Background: Angiogenesis is essential for development, growth and advancement of solid tumors.
Introduction
Angiogenesis is essential for development, growth and advancement of solid tumors [1] . The angiogenic factors vascular endothelial growth factor (VEGF), platelet-derived endothelial cell growth factor (PD-ECGF) identified with thymidine phosphorylase (TP), basic fibroblast growth factor (bFGF) and interleukin (IL)-8 work on angiogenesis in uterine cancers [2] [3] [4] [5] [6] [7] [8] [9] [10] . The expression of VEGF, and in particular its VEGF 165 and VEGF 121 isomers, decreased with advancement of clinical stage and with dedifferentiation in uterine endometrial adenocarcinomas [3] . PD-ECGF expression was significantly higher in well-differentiated adenocarcinomas (G1) than in moderately differentiated adenocarcinomas (G2) and poorly differentiated adenocarcinomas (G3) [7] . Conversely, bFGF expression increased with advancement of clinical stage and with dedifferentiation. VEGF expression in a welldifferentiated endometrial cancer cell line was sensitively regulated by ovarian steroids [11] , and PD-ECGF expression in uterine endometrium was also sensitively regulated by ovarian steroids [12] . These results indicate that VEGF and PD-ECGF expressions might be down-regulated with dedifferentiation. Therefore, if VEGF and PD-ECGF expression in G1, and bFGF expression in G2 and G3 can be suppressed by the use of tumor dormancy therapy, patient prognosis should be improved remarkably without the severe side effects seen with chemotherapy. Because the effects of chemotherapy are not specific to cancer cells, it can produce severe side-effects in normal cells, especially bone marrow cells. On the other hand, tumor dormancy therapy is specific to the rapidly growing vascular endothelial cells in tumors, and has no effect on slow-growing vascular endothelial cells or other normal cells. However, if an angiogenic factor is suppressed by tumor dormancy therapy over a long period of time, another angiogenic factor might be induced by an alternately linked angiogenic pathway, a process referred to as tolerance.
During angiogenesis, ETS-1 is strongly expressed in vascular endothelial cells and the adjacent interstitial cells [13] . Once angiogenesis has ended, there is a distinct downregulation of ETS-1 expression [14, 15] . The representative angiogenic factors VEGF and bFGF immediately induce ETS-1 expression in the early stages of angiogenesis, while the inhibition of ETS-1 expression leads to suppression of angiogenesis [16, 17] . Proteases urokinase type-plasminogen activator (u-PA), matrix metalloprotease (MMP)-1, MMP-3 and MMP-9 conserve an ETS-binding motif, and transcription factor ETS-1 converts vascular endothelial cells to angiogenic phenotypes by inducing proteases u-PA, MMP-1, MMP-3 and MMP-9 and integrin β3 gene expression [18, 19] . This status prompted us to study whether transcription factor ETS-1 works as an angiogenic mediator and, if so, which angiogenic factors link to ETS-1 for angiogenesis in uterine endometrial cancers, with the goal of formulating an efficient tumor dormancy therapy.
Materials and methods

Patients
Prior informed consent for the following studies was obtained from all patients and the Research Committee for Human Subjects, Gifu University School of Medicine. Sixty patients with uterine endometrial cancers (stage I, 25 cases; stage II, 19 cases and stage III, 16 cases; and G1, 30 cases; G2, 20 cases and G3, 10 cases) ranging from 35 to 79 years of age underwent (curative) surgery at the Department of Obstetrics and Gynecology, Gifu University School of Medicine, between December 1995 and January 1999. None of the patients had received any therapy before the uterine endometrial cancer tissue was taken. A sample of this tissue was snap-frozen in liquid nitrogen to determine the levels of ets-1 mRNA, VEGF, bFGF, PD-ECGF and IL-8, and another sample was submitted for histopathological study including immunohistochemical staining for ETS-1 and factor-VIII related antigen. The clinical stage of uterine endometrial cancers was determined by International Federation of Obstetrics and Gynecology (FIGO) classification [20] .
Preparation of internal standard recombinant RNA (rcRNA) for competitive RT-PCR and Southern blot analysis [21]
Deoxynucleic acid construction of the internal standard was originated and synthesized by PCR from a BamH/EcoRI fragment of V-erbB (Clontech, Palo Alto, CA, USA) with two sets of oligonucleotide primer sequences. The sequences for the first set of primers for ets-1 mRNA (MIMIC ets-1-5′ and MIMIC ets-1-3′) in the first PCR were as follows: MIMIC ets-1-5′, 5′-ATGGAGTCAACCCAGCCTATCGCAAGTGA-AATCTCCTCCG-3′; MIMIC ets-1-3′, 5′-CCATGCACATGTTGTCT-GGGTCTGTCAATGCAGTTTGTAG-3′ [22, 23] . The sequences for the second set of primers for ets-1 mRNA (MIMIC ets-1-P and ets-1-3′) in the secondary PCR were as follows: MIMIC ets-1-P, 5′-TAATACGACT-CACTATAGGATGGAGTCAACCCAGC CTAT-3′; ets-1-3′, 5′-CCAT-GCACATGTTGTCTGGG-3′. The first and second PCRs were carried out as previously described [21] . The second PCR products were transcribed using T7 RNA polymerase (Gibco BRL, Gaithersberg, MD, USA) and the amount of transcribed internal marker was calculated as previously described [21] .
Competitive RT-PCR and Southern blot analysis
Total RNA was isolated from tissues by the acid guanidium thiocyanatephenol-chloroform extraction method [24] . To obtain a standard curve each time, total RNA (3 µg) and a series of diluted recombinant RNA for ets-1 mRNA (1-100 fmol) were reverse transcribed. Primer sequences used to amplify the ets-1 gene (ets-1-5′ and ets-1-3′) were as follows: ets-1-5′, 5′-ATGGAGTCAACCCAGCCTAT-3′ (exon 5); ets-1-3′, 5′-CCATGCACATGTTGTCTGGG-3′ (exon 6). Competitive PCR was carried out as previously described [21] . In the competitive RT-PCR and Southern blot analysis for ets-1 mRNA, only two predicted sizes of DNA fragment were hybridized with the biotinylated ets-1-5′ probe to determine quantity as previously described [21] . As a negative control, no ets-1 mRNA was detected without reverse transcription in 30 cycles of PCR. Levels of ets-1 mRNA were determined using a standard curve and a serial dilution of rcRNA in competitive RT-PCR and Southern blot analyses, as shown in Figure 1 .
Immunohistochemistry
Sections (4 µm) of formalin-fixed paraffin-embedded tissues of uterine endometrial cancers were cut with a microtome and dried overnight at 37°C on a silanized slide (Dako, Carpinteria, CA, USA). Samples were deparaffinized in xylene at room temperature for 80 min and washed with a graded ethanol/water mixture and then with distilled water. The samples for ETS-1 were soaked in citrate buffer and then microwaved at 100°C for 10 min, and those for factor VIII-related antigen were treated with 0.3 µg/ml trypsin in phosphate buffer at room temperature for 20 min. The protocol for a DAKO LSAB2 kit, Peroxidase (Dako) was followed for each sample. In the described procedures, rabbit anti-human ETS-1 (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and rabbit antifactor VIII-related antigen (Zymed, San Francisco, CA, USA) were used at dilutions of 1:2000 and 1:2, respectively, as the first antibodies. The addition of the first antibody, rabbit anti-human ETS-1 or rabbit antifactor VIII-related antigen, was omitted in the protocols for negative controls of ETS-1 or factor VIII-related antigen, respectively. Vessels were counted in the five highest density areas at 200× magnification (using a combination of 20× objective and 10× ocular, 0.785 mm 2 per field). Microvessel counts were expressed as the mean numbers of vessels in these areas [25] . Microvessel density was evaluated by the counting of microvessels.
Enzyme immunoassay for determination of bFGF, VEGF, PD-ECGF and IL-8 antigens
All steps were carried out at 4°C. Uterine endometrial cancers tissue (wet weight 10-20 mg) was homogenized in HG buffer (5 mM Tris-HCl pH 7.4, 5 mM NaCl, 1 mM CaCl 2 , 2 mM ethyleneglycol-bis-[β-aminoethyl ether]-N,N,N′,N′-tetraacetic acid, 1 mM MgCl 2 , 2 mM DTT, 25 µg/ml aprotinin and 25 µg/ml leupeptin) with a Polytron homogenizer (Kinematics, Luzern, Switzerland). This suspension was centrifuged in a microfuge at 12 000 r.p.m. (10 000 g) for 3 min to obtain the supernatant. The protein concentration of samples was measured by the method of Bradford [26] to standardize VEGF, bFGF, PD-ECGF and IL-8 antigen levels.
Basic FGF, VEGF and IL-8 antigen levels in the samples were determined by a sandwich enzyme immunoassay using Human bFGF, VEGF and IL-8 Quantikine kits (R&D System, Minneapolis, MN, USA), respectively. PD-ECGF antigen levels were determined by the method of Nishida et al. [27] . The levels of bFGF, VEGF, PD-ECGF and IL-8 were standardized with the corresponding cellular protein concentrations.
Statistics
Levels of ets-1 mRNA, VEGF, bFGF, PD-ECGF and IL-8 were measured from three parts taken from each tissue, and the assay for each sample was carried out in triplicate. The t-test for two independent samples was used to compare the determinations in Figure 4 . The sample correlation coefficient was used for the comparisons in Figures 3, 5 and 6. Differences were considered significant for values of P <0.05.
Results
Immunohistochemical staining for ETS-1 and factor VIIIrelated antigen in a representative case of G2, stage IIb is shown in Figure 2 . Factor VIII-related antigen was clearly distributed in vascular endothelial cells. ETS-1 was also distributed in vascular endothelial cells and in the adjacent interstitium. There was a significant correlation between microvessel counts (MVC) and ets-1 mRNA levels (P <0.001) in uterine endometrial cancers (Figure 3) .
Ets-1 mRNA levels tended to increase with increasing disease stage of uterine endometrial cancers (Figure 4 ). There was a significant correlation between ets-1 mRNA and VEGF (P <0.001) in G1 ( Figure 5 ), but not between ets-1 mRNA and bFGF, PD-ECGF or IL-8 (data not shown). There was a significant correlation between ets-1 mRNA and bFGF (P <0.001) in G2 and G3 (Figure 6 ), but not between ets-1 mRNAs and VEGF, PD-ECGF or IL-8 (data not shown).
Additionally, there was a significant correlation between MVC and VEGF in G1 (P <0.001) and in all cases (P <0.05), and between MVC and bFGF in G2 and G3 (P <0.001) and in all cases (P <0.05) (data not shown).
Discussion
Ets-1 is expressed in a variety of cancer cells including gastric, pancreatic, esophageal, hepatocellular and cholangiocellular carcinomas, and thyroid and astrocytic tumors, and acts as a proto-oncogene during tumor progression [28] [29] [30] [31] [32] [33] [34] . ETS-1 is up-regulated and is involved in the overexpression of MMP-7 in hepatocellular carcinoma cells [35] , and positively regulates the expression of uPA in breast cancer, glioma, astrocytoma and meningioma cells, related to invasive potential and phenotypes [36] [37] [38] [39] . ETS-1 expression is induced by bFGF in glioma cells, related to invasive potential [37] , and by VEGF in astrocytoma, related to angiogenesis [40] . Furthermore, overexpressed ETS-1 is recognized as an angiogenic mediator in oral squamous cell carcinomas and gastric carcinomas [41, 42] .
In the current study, transcription factor ETS-1 was dominantly expressed in vascular endothelial cells and their adjacent interstitium, but not in cancer cells in uterine endometrial cancers, while ets-1 mRNA levels correlated with microvessel density observed in immunohistochemical staining for factor VIII-related antigen. Generally, distinct ETS-1 expression in vascular endothelial cells has been recognized as evidence of accelerated angiogenesis [13] [14] [15] . The present data reveal that ets-1 mRNA levels increased with increasing disease stage in uterine endometrial cancers. Therefore, ETS-1 might be activated as a direct angiogenic mediator for the initiation and maintenance stages of angiogenesis, and may possibly be an excellent indicator of patient prognosis in uterine endometrial cancers.
Since levels of ets-1 mRNA in this study correlated with levels of VEGF in G1 and bFGF in G2 and G3, it can be concluded that in all cases VEGF and bFGF act as angiogenic factors in uterine endometrial cancers, especially VEGF in G1 and bFGF in G2 and G3. We previously reported that VEGF expression was down-regulated with dedifferentiation (G1→G2→G3) [3] and conversely bFGF expression was upregulated with dedifferentiation in uterine endometrial cancers [9] . This indicates that ETS-1 is an angiogenic mediator linked to VEGF in G1 and bFGF in G2 and G3, and preserves angiogenic switching in the linkage to angiogenic factors to maintain advancement. Also, it is well known that bFGF and VEGF induce ETS-1 expression in vascular endothelial cell lines [16, 17] . Therefore, even if VEGF or bFGF can be suppressed by some agents, angiogenesis might be suppressed only transiently, which could lead to a temporary suppression of tumor growth and secondary spreading. In such a scenario, other angiogenic factors would be induced, and link to ETS-1 in the recruitment for alternate angiogenic activation, as a kind of tolerance to angiogenic inhibitors. Therefore, suppression of the major angiogenic factors along with suppression of ETS-1 recruitment might be more effective as a tumor dormancy therapy than mere suppression of major angiogenic factors. A specific inhibitor for ETS-1, transdominant mutant ETS-1, has already been shown to act as a dominant negative molecule and can be used as an efficient tool for angiogenic inhibition [43] .
